Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9617261 | 1.00 | SLC34A1 (0.55) | — | |
| Phosphoric Acid SCHEMBL433859 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL1284582 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL3432 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL36117 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL2811666 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL32680448 | 0.89 | — | — | |
| Phosphoric Acid SCHEMBL2900912 | 0.88 | SLC34A1 (0.55) | — | |
| Phosphoric Acid SCHEMBL2039374 | 0.88 | — | — | |
| Phosphoric Acid SCHEMBL9558597 | 0.88 | SLC34A1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116891839-A | Monoamine oxidase and application thereof | 青岛清原化合物有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023185184-A1 | MONOAMINE OXIDASE AND APPLICATION THEREOF | 青岛清原化合物有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023169071-A1 | MONOAMINE OXIDASE AND USE THEREOF | 青岛清原化合物有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-116731991-A | Monoamine oxidase and application thereof | 青岛清原化合物有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20160129072-A1 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2016-05-12 | — | — | US | disclosed |
| EP-1010435-B1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | MARUHO K K (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-1010435-A1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | Maruho K.K. (JP) | 2000-06-21 | — | — | EP | disclosed |
| US-4717657-A | COMPLEMENT ACTIVATION, QUANTITATIVE ANALYSIS | E. R. SQUIBB & SONS, INC. (US) | 1988-01-05 | — | — | US | disclosed |